Drugs / Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02111850 | Feb 2014 → Mar 2021 | breast cancer, cervical cancer, kidney cancer, melanoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111850 ↗ |
| Action | Deplete | “genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells” NCT02111850 ↗ |
| Modality | Cell therapy | “ex vivo tumor reactive, TCR gene-transduced peripheral blood mononuclear cells (PBMC)” NCT02111850 ↗ |
| Route | Intravenous | “Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes” NCT02111850 ↗ |